Focal Segmental Glomerulosclerosis
- PMID: 28242845
- PMCID: PMC5338705
- DOI: 10.2215/CJN.05960616
Focal Segmental Glomerulosclerosis
Erratum in
-
Correction.Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1889. doi: 10.2215/CJN.12071018. Epub 2018 Nov 9. Clin J Am Soc Nephrol. 2018. PMID: 30413403 Free PMC article. No abstract available.
Abstract
Focal segmental glomerulosclerosis (FSGS) is a leading cause of kidney disease worldwide. The presumed etiology of primary FSGS is a plasma factor with responsiveness to immunosuppressive therapy and a risk of recurrence after kidney transplant-important disease characteristics. In contrast, adaptive FSGS is associated with excessive nephron workload due to increased body size, reduced nephron capacity, or single glomerular hyperfiltration associated with certain diseases. Additional etiologies are now recognized as drivers of FSGS: high-penetrance genetic FSGS due to mutations in one of nearly 40 genes, virus-associated FSGS, and medication-associated FSGS. Emerging data support the identification of a sixth category: APOL1 risk allele-associated FSGS in individuals with sub-Saharan ancestry. The classification of a particular patient with FSGS relies on integration of findings from clinical history, laboratory testing, kidney biopsy, and in some patients, genetic testing. The kidney biopsy can be helpful, with clues provided by features on light microscopy (e.g, glomerular size, histologic variant of FSGS, microcystic tubular changes, and tubular hypertrophy), immunofluorescence (e.g, to rule out other primary glomerulopathies), and electron microscopy (e.g., extent of podocyte foot process effacement, podocyte microvillous transformation, and tubuloreticular inclusions). A complete assessment of renal histology is important for establishing the parenchymal setting of segmental glomerulosclerosis, distinguishing FSGS associated with one of many other glomerular diseases from the clinical-pathologic syndrome of FSGS. Genetic testing is beneficial in particular clinical settings. Identifying the etiology of FSGS guides selection of therapy and provides prognostic insight. Much progress has been made in our understanding of FSGS, but important outstanding issues remain, including the identity of the plasma factor believed to be responsible for primary FSGS, the value of routine implementation of genetic testing, and the identification of more effective and less toxic therapeutic interventions for FSGS.
Keywords: Alleles; Biopsy; Body Size; Electron; Fluorescent Antibody Technique; Focal Segmental; Genetic Testing; Glomerulosclerosis; Humans; Kidney Diseases; Kidney Glomerulus; Microscopy; Mutation; Penetrance; Podocytes; Segmental glomerulosclerosis; Workload; hypertrophy; immunosuppression; kidney; kidney transplantation; nephrotic syndrome.
Copyright © 2017 by the American Society of Nephrology.
Figures
Similar articles
-
Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation.Nephron. 2020;144 Suppl 1:65-70. doi: 10.1159/000510748. Epub 2020 Dec 1. Nephron. 2020. PMID: 33260184 Review.
-
Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.Nephron. 2020;144(9):413-427. doi: 10.1159/000508099. Epub 2020 Jul 28. Nephron. 2020. PMID: 32721952 Review.
-
Focal segmental glomerulosclerosis complicating solitary kidney.Clin Exp Nephrol. 2009 Feb;13(1):81-4. doi: 10.1007/s10157-008-0076-z. Epub 2008 Aug 9. Clin Exp Nephrol. 2009. PMID: 18688570
-
Identification of Novel Genetic Risk Factors for Focal Segmental Glomerulosclerosis in Children: Results From the Chronic Kidney Disease in Children (CKiD) Cohort.Am J Kidney Dis. 2023 Jun;81(6):635-646.e1. doi: 10.1053/j.ajkd.2022.11.003. Epub 2023 Jan 6. Am J Kidney Dis. 2023. PMID: 36623684
-
Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis.Clin J Am Soc Nephrol. 2020 Jul 1;15(7):964-972. doi: 10.2215/CJN.00590120. Epub 2020 May 22. Clin J Am Soc Nephrol. 2020. PMID: 32444394 Free PMC article.
Cited by
-
Multiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis.Transplant Direct. 2024 May 28;10(6):e1651. doi: 10.1097/TXD.0000000000001651. eCollection 2024 Jun. Transplant Direct. 2024. PMID: 38817628 Free PMC article.
-
Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease.Clin Sci (Lond). 2024 Jun 5;138(11):645-662. doi: 10.1042/CS20240249. Clin Sci (Lond). 2024. PMID: 38808486 Free PMC article. Review.
-
Dach1 is essential for maintaining normal mature podocytes.PLoS One. 2024 May 28;19(5):e0303910. doi: 10.1371/journal.pone.0303910. eCollection 2024. PLoS One. 2024. PMID: 38805434 Free PMC article.
-
Adhesion G Protein-Coupled Receptor Gpr126 (Adgrg6) Expression Profiling in Diseased Mouse, Rat, and Human Kidneys.Cells. 2024 May 18;13(10):874. doi: 10.3390/cells13100874. Cells. 2024. PMID: 38786096 Free PMC article.
-
A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations.Kidney Med. 2024 Apr 17;6(6):100826. doi: 10.1016/j.xkme.2024.100826. eCollection 2024 Jun. Kidney Med. 2024. PMID: 38765809 Free PMC article.
References
-
- D’Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 365: 2398–2411, 2011 - PubMed
-
- Sethi S, Glassock RJ, Fervenza FC: Focal segmental glomerulosclerosis: Towards a better understanding for the practicing nephrologist. Nephrol Dial Transplant 30: 375–384, 2015 - PubMed
-
- D’Agati VD: Pathobiology of focal segmental glomerulosclerosis: New developments. Curr Opin Nephrol Hypertens 21: 243–250, 2012 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous